Standard background therapy

Preclinical

Standard background therapy is one of 11 therapeutic programs targeting Primary Biliary Cholangitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Biliary CholangitisNot yet recruiting

Primary Biliary CholangitisPreclinical

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Primary Biliary Cholangitis

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

1 2

Ocaliva

IIntercept Pharmaceuticals

Approved

4 3

Iqirvo

Ipsen

Phase 3

3 4

Tricor

JJagotec

Phase 3

4 5

Lipaglyn

ZZydus Therapeutics Inc.

Phase 3

5 6

Selincro

IIndivior Inc.

Phase 2

1 7

CS0159

CCascade Pharmaceuticals, Inc

Phase 3

2 8

Seladelpar

Gilead

Phase 3

6 9

Volixibat

MMirum Pharmaceuticals, Inc.

Phase 2

1 10

Standard background therapy

BBeijing 302 Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Primary Biliary Cholangitis

NCT07795151

Clinical

Trials by Indication[1]

Primary Biliary Cholangitis1 trial

A Phase I/II Clinical Study of Human Umbilical Cord-Derived Mesenchymal Stromal Cells in the Treatment of Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid

Not yet recruiting·BBeijing 302 Hospital·Preclinical·NCT07795151·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard background therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard background therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Beijing 302 Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: BBeijing 302 Hospital

Standard background therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Primary Biliary Cholangitis1 trial

References

Drug Info

Quick Facts

Related News